Greenwich Lifesciences Earnings Estimate
| GLSI Stock | USD 25.43 1.57 5.81% |
Greenwich | Build AI portfolio with Greenwich Stock |
Greenwich Lifesciences Earnings Estimation Breakdown
The calculation of Greenwich Lifesciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Greenwich Lifesciences is estimated to be -0.33625 with the future projection ranging from a low of -0.37 to a high of -0.3025. Please be aware that this consensus of annual earnings estimates for Greenwich Lifesciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.37 Lowest | Expected EPS | -0.3 Highest |
Greenwich Lifesciences Earnings Projection Consensus
Suppose the current estimates of Greenwich Lifesciences' value are higher than the current market price of the Greenwich Lifesciences stock. In this case, investors may conclude that Greenwich Lifesciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Greenwich Lifesciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 2 | 50.0% | 0.0 | -0.33625 | -1.46 |
Greenwich Lifesciences Earnings per Share Projection vs Actual
Actual Earning per Share of Greenwich Lifesciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Greenwich Lifesciences predict the company's earnings will be in the future. The higher the earnings per share of Greenwich Lifesciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Greenwich Lifesciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Greenwich Lifesciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Greenwich Lifesciences should always be considered in relation to other companies to make a more educated investment decision.Greenwich Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Greenwich Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-10 | 2025-09-30 | -0.23 | -0.33 | -0.1 | 43 | ||
2025-08-14 | 2025-06-30 | -0.24 | -0.3 | -0.06 | 25 | ||
2025-05-19 | 2025-03-31 | -0.24 | -0.25 | -0.01 | 4 | ||
2025-02-26 | 2024-12-31 | -0.21 | -0.61 | -0.4 | 190 | ||
2024-11-08 | 2024-09-30 | -0.21 | -0.2 | 0.01 | 4 | ||
2024-08-21 | 2024-06-30 | -0.2 | -0.2 | 0.0 | 0 | ||
2024-05-20 | 2024-03-31 | -0.2 | -0.19 | 0.01 | 5 | ||
2024-03-31 | 2023-12-31 | -0.22 | -0.2138 | 0.0062 | 2 | ||
2023-10-19 | 2023-09-30 | -0.22 | -0.1862 | 0.0338 | 15 | ||
2023-08-21 | 2023-06-30 | -0.23 | -0.13 | 0.1 | 43 | ||
2023-05-22 | 2023-03-31 | -0.23 | -0.16 | 0.07 | 30 | ||
2023-03-01 | 2022-12-31 | -0.22 | -0.22 | 0.0 | 0 | ||
2022-11-14 | 2022-09-30 | -0.19 | -0.18 | 0.01 | 5 | ||
2022-08-15 | 2022-06-30 | -0.19 | -0.06 | 0.13 | 68 | ||
2022-05-20 | 2022-03-31 | -0.19 | -0.15 | 0.04 | 21 | ||
2022-03-21 | 2021-12-31 | -0.07 | -0.18 | -0.11 | 157 | ||
2021-11-15 | 2021-09-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2021-08-13 | 2021-06-30 | -0.06 | -0.06 | 0.0 | 0 | ||
2021-05-20 | 2021-03-31 | -0.26 | -0.05 | 0.21 | 80 | ||
2021-03-31 | 2020-12-31 | -0.93 | -0.12 | 0.81 | 87 | ||
2020-11-16 | 2020-09-30 | -0.03 | -0.03 | 0.0 | 0 | ||
2020-09-28 | 2020-06-30 | 0 | -0.02 | -0.02 | 0 | ||
2020-06-23 | 2020-03-31 | 0 | -0.02 | -0.02 | 0 | ||
2020-01-28 | 2019-12-31 | 0 | -0.27 | -0.27 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -1.1516 | -1.1516 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -12.828 | -12.828 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.7327 | -0.7327 | 0 |
About Greenwich Lifesciences Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Greenwich Lifesciences earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Greenwich Lifesciences estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Greenwich Lifesciences fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -59.5 M | -56.6 M | |
| Retained Earnings Total Equity | -30.3 M | -31.8 M | |
| Earnings Yield | (0.11) | (0.12) | |
| Price Earnings Ratio | (8.33) | (8.75) | |
| Price Earnings To Growth Ratio | (0.11) | (0.12) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is there potential for Biotechnology market expansion? Will Greenwich introduce new products? Factors like these will boost the valuation of Greenwich Lifesciences. Market participants price Greenwich higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Investors evaluate Greenwich Lifesciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Greenwich Lifesciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. External factors like market trends, sector rotation, and investor psychology can cause Greenwich Lifesciences' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Greenwich Lifesciences' market price signifies the transaction level at which participants voluntarily complete trades.